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Abstract	  
1.	  Introduction	  The	  inflammatory	  bowel	  diseases	  (IBD)	  are	  chronic	  inflammatory	  diseases	  of	  the	  gastrointestinal	  (GI)	  tract	  that	  are	  associated	  with	  significant	  morbidity	  and	  disability.	  Over	  the	  past	  few	  decades,	  biological	  therapy	   with	   anti-­‐Tumor	   Necrosis	   Factor	   agents	   (anti	   TNF-­‐α)	   has	   emerged	   as	   a	   corner	   stone	   of	  treatment	  for	  IBD.	  Despite	  significant	  response	  and	  remission	  rates,	  clinicians	  are	  often	  confronted	  to	  secondary	  loss	  of	  responses	  or	  side	  effects	  during	  long	  term	  maintenance.	  There	  is	  emerging	  data	  from	  the	   literature	   suggesting	   that	   infliximab	   trough	   levels	   might	   help	   clinicians	   tailoring	   therapy	   and	  overcome	  on-­‐treatment	  IBD	  flares.	  
2.	  Study	  aims	  To	  evaluate	  the	  indications	  for	  trough	  anti-­‐TNF-­‐α	  and	  ADA	  serum	  testing,	  the	  prevalence	  of	  ADA	  and	  the	   therapeutic	   range	  of	   anti-­‐TNF	   trough	   level	  measures	   and	   to	   assess	   the	   clinical	   impact	   of	   trough	  anti-­‐TNF-­‐α	  and	  ADA	  serum	  levels	  on	  routine	  management	  of	  IBD	  patients	  
3.	  Study	  Design	  This	  is	  a	  retrospective	  study	  of	  anti-­‐TNF	  trough	  level	  and	  ADA	  serum	  determinations	  in	  IBD	  patients	  receiving	   anti-­‐TNF	   agents.	   We	   included	   all	   therapeutic	   drug	   monitoring	   measurements	   performed	  from	  05.03.2013	  to	  23.04.2014.	   	  A	  total	  of	  70	  patients	  where	   included	  between	  two	  tertiary	  referral	  centers.	  	  
3.1	  Inclusion	  criteria	  1.	  Adult	  patients	  affected	  with	  CD	  or	  UC.	  2.	  Patients	  for	  whom	  an	  anti-­‐TNF-­‐α	  trough	  level	  and	  /	  or	  anti-­‐	  drug	  antibodies	  were	  	  performed	  at	  CHUV.	  3.	  Current	  treatment	  by	  anti-­‐TNF-­‐	  α	  agents.	  
3.2.	  Exclusion	  criteria	  1.No	  IBD	  diagnosis.	  2.	  Adults	  patients	  suffering	  from	  another	  chronic	  inflammatory	  disease	  requiring	  treatment	   with	   anti-­‐TNF-­‐α	   such	   as	   rheumatoid	   arthritis.	   3.	   Treatment	   with	   anti-­‐TNF-­‐α	   interrupted	  before	  the	  assays.	  
Results	  	  In	  our	  patients	   (n=70)	  appear	  no	  male	  or	   female	  predominance	  and	   	   the	  average	  age	  was	  40	  years.	  Most	  tests	  (n=117)	  were	  performed	  for	  Crohn’s	  disease	  (73%).	  A	  large	  subset	  of	  our	  patients	  had	  been	  previously	   managed	   with	   immunomodulators	   (54.%).	   However,	   few	   cases	   were	   on	   combination	  therapy	  (10%).	  The	  great	  majority	  (79%)	  for	  the	  indication	  of	  the	  determinations	  were	  performed	  as	  “medical	  follow	  up”.	  The	  percentage	  of	  patients	  with	  an	  IFX	  trough	  level	  within	  the	  desired	  range	  (3-­‐8	  µg/ml)	   is	   at	   first	   determination	   rather	   low,	   but	   tends	   to	   increase	   during	   the	   subsequent	  determinations.	  Of	  117	  total	  tests	  assessed	  the	  results	  impacted	  treatment	  decisions	  in	  approximately	  40%	  of	  the	  cases.	  	  
Conclusion	  Therapetic	  drug	  monitoring	  will	  guide	  the	   induction,	   the	  dose	  titration	  to	  prevent	  disease	   flares	  and	  finally	   it	   will	   guide	   interventions	   for	   cases	   with	   loss	   of	   response	   to	   biologicals.	   However,	   some	  knowledge	  gaps	  still	  need	  to	  be	  addressed	  to	  confirm	  this	  strategy.	  We	  feel	  that	  after	  testing	  drug	  and	  ADA	  levels,	  clinicians	  may	  gain	  a	  sense	  of	  saliency	  in	  relation	  to	  decision-­‐making	  not	  only	  in	  cases	  with	  poor	  response	  to	  biologicals	  but	  even	  in	  stable	  case	  
	  
Clinical	  utility	  of	  anti-­‐TNF	  trough	  levels	  and	  anti-­‐drug	  antibodies	  in	  the	  management	  of	  inflammatory	  bowel	  disease	  	  
Davide	  Bianchetti	   2	  
Keywords:	  Inflammatory	  bowel	  disease/	  trough	  levels/	  anti-­‐TNF-­‐α/l	  adapted	  strategy	  /swiss	  
	  
List	  of	  symbols	  and	  abbreviations	  	  ADA	   	   Anti-­‐drug-­‐antibody	  CD	   	   Crohn’s	  disease	  	  EIMs	   	   Extraintestinal	  manifestations	  	  ESR	   	   Erythrocyte	  sedimentation	  rate	  FBM	   	   Faculté	  Biologie	  et	  Médecine	  GWAS	   	   Genome-­‐wide	  association	  studies	  	  G6PD	   	   Glucose	  6-­‐phosphate	  dehydrogenase	  IBD	   	   Inflammatory	  bowel	  disease	  	  UC	   	   Ulcerative	  colitis	   	  TNF-­‐α	  	   Tumor	  necrosis	  factor	  α	  ADA	   	   Anti-­‐drugs-­‐antibody	  ELISA	   	   Enzyme-­‐linked	  immunosorbent	  assay	  	  HMSA	   	   Homogenous	  mobility	  shift	  assay	  IFX	   	   Infliximab	  Y	   	   Years	  NSAIDs	   No-­‐steroidal	  Anti-­‐inflammatory	  Drugs	  NS	   	   Non	  significant	  RIA	  	   	   Radioimmunoassay	  WF	   	   Weighting	  factor	  TDM	   	   Therapeutic	  drug	  monitoring	  
Acknowledgement	  I	  would	   like	   to	   express	  my	   gratitude	   to	  my	   tutor	   Prof.	   Dorta	   for	   the	   chance	   to	   realize	   this	  Master	  thesis	  in	  the	  Gastroenterology	  domain.	  	  Furthermore	  I	  would	  like	  to	  thank	  Dr.	  Maillard,	  for	  introducing	  me	  to	  the	  topic,	  for	  the	  useful	  and	  precious	  remarks	  and	  comments	  through	  the	  whole	  process	  of	  this	  Master	  project.	  I	  would	  like	  also	  to	  thank	  the	  patients	  involved	  into	  the	  study	  and	  Prof.	  Michetti,	  who	  allowed	  me	  to	  consult	  the	  charts	  of	  his	  patients	  and	  collect	  original	  data.	  Also,	  I	  would	  like	  to	  thank	  Dr.	  Guirgis,	  who	  has	  shared	  her	  precious	  time	  and	  supported	  me	  throughout	  the	  entire	  process.	  
Clinical	  utility	  of	  anti-­‐TNF	  trough	  levels	  and	  anti-­‐drug	  antibodies	  in	  the	  management	  of	  inflammatory	  bowel	  disease	  	  
Davide	  Bianchetti	   3	  
	  
Index	  1.	  Introduction	  .................................................................................................................................................................	  4	  1.1	  Epidemiology	  .......................................................................................................................................................	  4	  1.2	  Etiology,	  Pathogenesis	  and	  risk	  factors	  ....................................................................................................	  4	  1.2.1	  Risk	  factors	  ...................................................................................................................................................	  6	  1.3	  Clinical	  manifestations	  of	  IBD	  .......................................................................................................................	  7	  1.3.1.	  Comparison	  between	  UC	  and	  CD	  .......................................................................................................	  7	  1.3.2.	  Extra-­‐intestinal	  manifestations	  ..........................................................................................................	  9	  1.3.3.	  Disease	  complications	  ............................................................................................................................	  9	  1.4	  Drug	  management	  .............................................................................................................................................	  9	  1.4.1	  Anti	  TNF-­‐α	  treatment	  ...........................................................................................................................	  10	  1.4.2	  Loss	  of	  response	  to	  anti	  TNF-­‐α	  agents	  and	  appropriate	  strategies	  ..................................	  13	  1.4.3	  New	  treatments	  approaches	  ..............................................................................................................	  14	  2.	  Study	  aims	  ..................................................................................................................................................................	  15	  3.	  Study	  Design	  .............................................................................................................................................................	  15	  3.1	  Inclusion	  criteria	  .............................................................................................................................................	  16	  3.2	  Exclusion	  criteria	  ............................................................................................................................................	  16	  4.	  Results	  .........................................................................................................................................................................	  17	  4.1	  Selection	  criteria	  .............................................................................................................................................	  17	  4.2	  Clinical	  demographic	  .....................................................................................................................................	  18	  4.3	  Indication	  ............................................................................................................................................................	  19	  4.4	  Assays	  results	  ...................................................................................................................................................	  20	  4.5	  Clinical	  approach	  .............................................................................................................................................	  21	  5.Discussion	  ...................................................................................................................................................................	  23	  6.	  Conclusion	  .................................................................................................................................................................	  25	  7.Bibliography	  ...............................................................................................................................................................	  26	  	  
	  	  
	  	  
Clinical	  utility	  of	  anti-­‐TNF	  trough	  levels	  and	  anti-­‐drug	  antibodies	  in	  the	  management	  of	  inflammatory	  bowel	  disease	  	  
Davide	  Bianchetti	   4	  
1.	  Introduction	  The	   inflammatory	   bowel	   diseases	   (IBD),	   which	   are	   comprised	   of	   Crohn’s	   disease	   (CD),	  ulcerative	   colitis	   (UC)	   and	   indeterminate	   colitis,	   are	   chronic	   inflammatory	   diseases	   of	   the	  gastrointestinal	   (GI)	   tract	   that	   are	   associated	   with	   significant	   morbidity	   and	   disability(1-­‐6).	  Apart	  from	  GI	  manifestations,	  IBD	  are	  associated	  with	  extra-­‐intestinal	  manifestations	  (EIM)(7).	  Over	   the	  past	   few	  decades,	  biological	   therapy	  with	  anti-­‐Tumor	  Necrosis	  Factor	  agents	   (anti	  TNF-­‐α)	  has	  emerged	  as	  a	  corner	  stone	  of	  treatment	  for	  IBD	  and	  its	  EIMs.	  Therapy	  with	  these	  agents	   can	   achieve	   mucosal	   healing,	   reduce	   the	   number	   of	   hospitalizations	   and	   reduce	  surgery	   and	   ameliorate	   quality	   of	   life	   (8).	   Although	   a	   large	   number	   of	   patients	   benefit	   from	  those	  treatments,	  a	  limiting	  factor	  for	  the	  use	  of	  these	  agents	  is	  primary	  non-­‐response,	  loss	  of	  response	  or	  intolerance	  (9).	  A	  precise	  rate	  of	  primary	  non-­‐response	  is	  not	  easy	  to	  find	  in	  the	  literature	   especially	   because	  of	   different	  use	  of	   definitions,	   but	   it	   is	   estimated	   that	   primary	  non-­‐responders	  rates	  correspond	  to	  around	  40%	  of	  anti-­‐TNF	  treated	  patients(10).	  In	  addition,	  in	  patients	  initially	  responding	  to	  treatment,	  secondary	  loss	  of	  response	  can	  be	  noted	  in	  21%	  to	  46%	  of	   the	   cases(10).	   To	   tackle	   those	   limiting	   factors	   and	   try	   to	   improve	  disease	   control,	  several	  clinicians	  make	  use	  of	  therapeutic	  drug	  monitoring	  strategies	  to	  guide	  management	  of	  IBD	  when	  TNF	  failure	  occurs.	  
1.1	  Epidemiology	  	  The	  geographic	  distribution	  of	  IBD	  is	  highly	  variable	  (11).	  For	  instance,	  the	  prevalence	  of	  IBD	  is	  higher	  in	  northern	  Europe	  and	  North	  America	  than	  in	  Asia	  and	  the	  southern	  hemisphere	  (12).	  These	  diseases	  are	  observed	  predominantly	  in	  developed	  nations	  (13).	  However	  the	  incidence,	  especially	  in	  countries	  previously	  thought	  to	  have	  a	  low	  incidence,	  is	  rising	  (14).	  It	  is	  estimated	  that	  1.4	  million	  people	  in	  the	  United	  States	  of	  America	  (USA)	  are	  affected	  with	  IBD,	   whereas	   in	   Europe	   approximately	   2.2	   million	   suffer	   from	   this	   condition	   (14).	   In	  Switzerland,	  between	  12	  000	  and	  16	  000	  patients	  suffer	  from	  IBD	  (15,	  16).	  In	  general	  UC	  is	  more	  prevalent	  than	  CD	  (17).	  The	  male/female	  ratio	  is	  0.8	  for	  CD,	  and	  1.5	  for	  UC	  (18).	  IBD	  can	  occur	  at	  any	  age	  with	  a	  peak	  incidence	  between	  25-­‐45	  year	  (1,	  3,	  5,	  19).	  In	  adults	  UC	  is	  the	  most	  common	  form	  of	  IBD,	  whereas	  for	  children	  it	  is	  CD	  (12).	  
1.2	  Etiology,	  Pathogenesis	  and	  risk	  factors	  The	  ultimate	  cause	  of	  IBD	  is	  not	  well	  established	  (9,	  20,	  21),	  but	  significant	  progresses	  have	  been	  made	  (2).	  Overall,	  IBD	  can	  be	  considered	  as	  a	  dysregulation	  of	  the	  mucosal	  immune	  responses	  to	  commensal	  gut	  flora	  in	  a	  genetically	  predisposed	  host	  (1,	  5,	  11,	  17,	  20,	  22).	  Under	  normal	  conditions,	  equilibrium	  between	  the	  luminal	  content	  and	  the	  mucosal	  immune	  system	  exists.	  IBD	  can	  be	  the	  consequence	  of	  a	  breakdown	  balance	  in	  the	  gut	  mucosa,	  which	  results	  in	  an	  aberrant	  immune	  response	  against	  the	  commensal	  flora	  (1,	  5,	  7,	  11,	  17).	  This	  abnormal	  interaction	  leads	  to	  activation	  of	  adaptive	  immune	  responses	  that	  result	  in	  the	  production	  of	  inflammatory	  cytokines	  such	  as	  IL-­‐1,	  IL-­‐6,	  IL-­‐8	  and	  tumor	  necrosis	  factor	  alpha	  (TNF-­‐α)	   (7,	  20,	  22).	   These	   cytokines	   are	   capable	  of	  maintaining	   a	   strong	   inflammatory	   state	   in	  susceptible	  hosts	  (20).	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Figure	  1:	  Immunological	  mechanisms	  of	  IBD	  pathogenesis	  (1).	  
	  	  Figure	  1.	   Immunological	  mechanisms	  of	   IBD	  pathogenesis	   (1)	   .	  Section	  A	  shows,	   in	  a	  healthy	  person,	  a	  normal	  lamina	  propria	  and	  some	  immune	  cells	  which	  secrete	  cytokines.	  These	  are	  pro-­‐inflammatory	  and	  anti-­‐inflammatory.	  An	  homeostatic	  equilibrium	   is	  maintained.	  On	   the	  contrary,	   section	   B	   shows	   a	   person	   with	   intestinal	   inflammation.	   The	   mucosal	   layer	   is	  interrupted	   and	   epithelial	   tight	   junctions,	  which	   normally	  maintain	   intestinal	   permeability,	  are	   disrupted.	   In	   IBD,	   immune	   cells	   react	   and	   produce	   pro-­‐inflammatory	   cytokines,	   which	  recruit	  additional	   leukocytes	  by	  preserving	  a	  cycle	  of	   inflammation.	  Red	   labels	  denote	  some	  therapeutic	  approaches	  (1).	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1.2.1	  Risk	  factors	  	  Two	  main	  categories	  of	  risk	  factors	  have	  been	  described	  for	  IBD:	  Genetic	  predisposition	  (23),(24)	  :	  Evidence	  for	  a	  genetic	  factor	  associated	  with	  IBD	  comes	  from	  several	   observations.	   First,	   a	   positive	   family	   history	   increases	   disease	   risk	   in	   a	   significant	  manner	   (23,	   25).	   For	   example,	   for	   CD,	   the	   concordance	   rate	   for	   monozygotic	   twins	   is	  approximately	  50%(11).	  Moreover	  there	  appears	  to	  be	  concordance	  with	  disease	  distribution	  in	  family	  members	  (11).	  In	  comparison,	  concerning	  UC,	  the	  concordance	  of	  monozygotic	  twins	  is	  only	  16%	  (11).	   IBD	  are	  more	  common	  in	  whites	  and	  Jews,	  and	  indeed	  Jewish	  descent	  is	  an	  independent	  risk	   factor	   for	   the	  disorder	   (21).	  Finally,	  and	  most	   importantly,	  several	  genome-­‐wide	   association	   studies	   (GWAS)	  have	   identified	   specific	   genetic	   anomalies	   associated	  with	  IBD.	   Some	   of	   the	   major	   genetic	   mutations	   include	   genes	   implicated	   in	   innate	   immune	  responses	  such	  as:	  NOD2,	  ATG16L1	  and	  on	  the	  adaptive	  immunity	  such	  as	  IL-­‐23R.	  	  	  Environmental:	   in	   addition	   to	   ethnic	   and	   genetic	   predisposition,	   several	   environmental	  factors	   have	   been	   described	   as	   disease	   modifiers	   including	   in	   a	   non-­‐exhaustive	   way	   (23):	  	  antibiotic	  use,	  smoking,	  appendicectomy,	  breast	   feeding,	  sleep	  and	  stress.	  All	  environmental	  factors	  that	  have	  putative	  roles	  in	  disease	  onset	  and	  flares	  are	  generically	  grouped	  under	  the	  label	  “exposome”	  (26).	  According	  to	  the	  so-­‐called	  “hygiene	  hypothesis”,	  the	  low	  frequency	  of	  infections	  in	  developed	  countries	  causes	  an	  increasing	  incidence	  of	  various	  conditions.	  The	  role	  of	  poor	  hygiene	  as	  a	  prevention	  of	   IBD	  has	  been	  reported	   (25)	  Furthermore,	  developing	  countries,	  which	  recently	  changed	  their	  lifestyle,	  have	  seen	  their	  incidence	  of	  IBD	  increased	  (17,	  18).	  A	   critical	   component	   of	   the	   “exposome”	   is	   the	  microbiome,	   defined	   as	   the	   entire	   intestinal	  commensal	   bacterial	   community	   (21).	  The	   literature	   shows	   that	   a	   reduced	   diversity	   and	   an	  alteration	   of	   the	   composition	   and	   the	   organization	   of	   the	   commensal	  microbiota	   can	   drive	  intestinal	   inflammation	   in	   genetically	   susceptible	   individuals	   (21).	   To	   date,	   it	   is	   currently	  unclear	  whether	  microbial	  changes	  associated	  with	  IBD	  are	  a	  cause	  or	  consequence	  of	  disease.	  It	   is	  also	  unclear	  whether	  therapeutic	  strategies	  aimed	  at	  modulating	  microbial	  composition	  are	  promising	  as	  most	  studies	  on	  probiotics	  failed	  to	  show	  any	  benefits	  and	  fecal	  microbiota	  transplantation	  shows	  marginal	  benefits,	  if	  any.	  	  
Smoking	  is	  a	  relevant	  behavioral	  factor	  that	  modulates	  IBD	  development	  and	  intensity..	  It	  is	  indeed	  associated	  with	  an	  increased	  risk	  of	  CD	  onset	  and	  disease	  exacerbation.	  In	  contrast,	  it	  is	  partially	  protective	  from	  UC	  (14).	  Non-­‐smokers	  and	  former	  smokers	  both	  have	  an	  increased	  risk	  of	  UC,	  whereas	  smoking	  exacerbates	  the	  course	  of	  CD.	  (27).	  Nationally,	  using	  the	  data	  from	  SIBDCS	   (n=1770)	   where	   patients	   were	   defined	   as	   smokers	   or	   non-­‐smokers	   based	   on	   self-­‐declaration	  we	  noted	  that,	  around	  30%	  of	  all	  IBD	  patients	  are	  smokers	  at	  present	  day	  (28).	  In	  this	  study,	  Smoking	  quantities	  were	  greater	  in	  Crohn’s	  disease	  patients	  compared	  to	  UC.	  This	  peculiarity	   is	   observed	   in	  Europe	   as	  well	   (28).	   Importantly,	  women	  with	  CD	  had	   the	  highest	  prevalence	  of	  smoking.	  As	  mentioned	  earlier,	  appendicectomy	  protects	  from	  the	  development	  of	  UC	  but	  can	  increase	  the	   risk	   of	   CD	   (14).	   One	   possible	   explanation	   for	   increased	   incidence	   of	   CD	   is	   the	   fortuitous	  discovery	  of	  CD	  in	  appendectomy	  piece.	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Finally,	  some	  drugs	  have	  been	  associated	  with	  IBD	  development	  including	  non	  steroidal	  anti-­‐inflammatory	  drugs	  (12)	  	   and	  oral	  contraceptives	   (14).	  Both	  of	   these	  drugs	  may	   indeed	   trigger	  disease	  flares	  and	  worsening	  of	  the	  underlying	  IBD.	  It	  is	  logic	  to	  think	  if	  what	  we	  eat	  every	  day	  has	  an	  impact	  the	  onset	  or	  the	  course	  of	  IBD,	  but	  right	  now	  clinicians	  are	  not	  yet	  able	  to	  fully	  answer	  to	  the	  question.	  Some	  studies,	  particularly	  on	  animal	  models,	  suggested	  that	  certain	  nutrients	  can	  reduce	  intestinal	  inflammation	  and	  on	  the	   contrary	   other	   can	   be	   deleterious.	   In	   the	   literature	   we	   find	   some	   progress	   of	   the	  understanding	  of	  the	  impact	  of	  a	  diet	  on	  IBD,	  but	  clear	  data	  are	  limited	  and	  controversial.	  For	  example	   the	   efficacy	   of	   omega-­‐3	   fatty	   acids	   for	   the	   maintenance	   of	   a	   medically	   induced	  remission	  in	  CD	  is	  not	  yet	  confirmed.	  (13)	  	  In	  conclusion,	  those	  data	  suggest	  a	  clear	  role	  for	  environmental	  factors	  in	  IBD	  factors	  that	  is	  currently	  under	  intense	  investigation	  in	  Switzerland	  and	  worldwide.	  	  
1.3	  Clinical	  manifestations	  of	  IBD	  
1.3.1.	  Comparison	  between	  UC	  and	  CD	  	  CD	   and	  UC	   are	   two	  well-­‐distinguished	   diseases.	   However,	   there	   are	   sometimes	   overlaps	   in	  their	   clinical	   presentation.	   The	   diagnosis	   and	   characterization	   of	   these	   diseases	   rely	   on	  clinical,	   endoscopic,	   radiological	   and	   pathologic	   criteria.	   (3,	   13,	   25,	   29)	   A	   comparison	   between	  these	  two	  IBD	  is	  depicted	  in	  table	  1.	  Table	  1:	  A	  comparison	  between	  these	  two	  inflammatory	  bowel	  diseases.	  	  
IBD	   Ulcerative	  colitis	  	  (UC)	   Crohn’s	  disease	  (CD)	  
Localization	   Rectum	  :	  50%	  Left	  colon	  :	  20-­‐30%	  Pancolitis	  :	  20%	  	  Rare:	  Backwash	  ileitis,	  ceacal	  patch	  	  
Any	  segment	  of	  the	  intestinal	  tract(4,	  20)	  Small	  intestine-­‐colon:	  (50-­‐60%)	  Rectum:	  30%	  Small	  intestine:	  25%	  	  	  Rare:	  esophagus,	  and	  stomach.	  	  	  	  
Age	   Two	  peaks	  of	  prevalence:	  40-­‐49	  and	  60-­‐69	  have	  been	  observed	  (16).	   The	   main	   prevalence	   of	   the	   diagnoses:	  17	  and	  40	  years	  (21).	  Peak	  of	  prevalence:	  30-­‐39	  years	  (16).	  
Symptoms	  	   Rectal	   bleeding,	   diarrhea,	   urgency,	  tenesmus,	   abdominal	   pain,	   fever,	   extra	  intestinal	  manifestations	  (17).	   Chronic	   diarrhea,	   abdominal	   pain,	  weight	   loss,	   intestinal	   obstructive	  symptoms,	   extra	   intestinal	  manifestations	  (13).	  	  
Pathology	   Non-­‐transmural	   =	   confined	   to	   the	  mucosa	  and	  submucosa(1,	  11)	   Transmural	  =	  inflammation	  affects	  the	  entire	  gastrointestinal	  wall	  (1,	  5,	  11,	  13).	  
Evolution	  of	  
the	  disease	  	  
Chronic	   inflammatory	   condition	  relapsing	  and	  remitting	  course(30)	  	   	  
•  25%	   of	   patients	   are	   in	   remission	  approximately	   3-­‐7	   years	   after	  diagnosis	  (25).	  
•  18%	  of	  patients	  have	  a	  relapse	  every	  year	  (25).	  
•  57%	  of	   patients	   experience	  periodic	  relapses	  (25).	  	  	  
•  The	   colectomy	   rate	   is	   estimated	   at	  24%	   after	   10	   years	   after	   diagnosis	  (25).	  
CD	  can	  evolve	  in	  different	  phenotypes.	  	  Non-­‐stricturing	  non-­‐	  penetrating:	  80%	  	  Other	   phenotypes:	   structuring,	  penetrating	   and	   perianally	   penetrating	  (21).	  
•  10-­‐30%	   of	   patients	   undergo	  exacerbation	   one	   year	   after	  diagnosis(25)	  
•  15-­‐25%	   of	   patients	   show	   a	   slight	  disease	  activity	  
•  55-­‐65%	  of	  patients	  are	  in	  remission,	  of	   which	   only	   10-­‐13%	   achieved	   a	  long	   remission	   over	   several	   years	  (25).	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•  80%	   of	   patients	   with	   CD	   will	  require	   surgery	   during	   their	  lifetime	  (31).	  
Diagnosis	   No	  gold	  standard	  Endoscopic,	   histological,	   radiological,	  biochemical	   investigations,	   negative	  stool	   examination	   for	   infectious	   cause	  are	  needed	  (32).	  





Truelove-­‐Witts	  severity	  score	  (33)	  :	  
mild:	  	  <4	  stools	  /	  day,	  pulse	  <90bpm,	  no	  fever,	  no	   anemia	   normal	   erythrocyte	  sedimentation	  rate	  (ESR)	  or	  normal	  CRP	  (30,	  33).	  Erythematous	  mucosa	  (20)	  
moderate:	  	  4-­‐6	   stools	   /	   day,	   minimal	   signs	   of	  systemic	  toxicity	  (30,	  33)	  Mucosal	  bleeding	  and	  ulcerated	  (20)	  
severe:	  	  >	   6	   stools	   /	   day	   containing	   blood,	  systemic	   toxicity,	   (fever,	   tachycardia,	  anemia,	   ESR	   and	   CRP	   increased)	   (30,	   33).	  Mucosal	  bleeding	  and	  ulcerated	  (20)	  	  
Crohn’s	  disease	  activity	  index	  (CDAI)	  (34)	  
mild:	  	  CDAI	  of	  150-­‐220	  The	  patient	  is	  eating	  well.	  	  No	  dehydration,	   fever,	   abdominal	  mass	  and	   no	   abdominal	   sensitivity	   to	  pressure.	  	  No	   weight	   loss>	   10%,	   no	   obstruction.	  CRP	  below	  the	  standard(13)	  
moderate:	  CDAI	   of	   220-­‐450	   the	   treatment	   of	  mild	  ineffective:	   fever,	   weight	   loss,	  abdominal	   pain,	   nausea,	   occasional	  vomiting	   without	   obstruction.	   CRP	  above	  the	  norm	  (13)	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1.3.2.	  Extra-­‐intestinal	  manifestations	  Figure	  2:	  The	  major	  extraintestinal	  manifestations	  (EIMs)	  and	  associate	  autoimmune	  disorders	  in	  IBD	  form(21)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Figure	  2.	  EIMs	  are	  a	  common	  problem	  in	  IBD,	  many	  patients	  with	  CD	  or	  UC	  can	  develop	  one	  of	  this	  EIMs	  during	  their	  life.	  Figure	  2	  shows	  the	  most	  important	  one.	  EIMs	  can	  be	  categorized	  in	  three	   different	   groups	   (35):	   1.	   reactive	   manifestations	   associated	   with	   intestinal	   disease	  activity	   (polyarticular	   arthritis	   and	   erythema	   nodosum)	   or	   not	   (pyoderma	   gangrenosum,	  uveitis).	   2.	   non-­‐IBD-­‐specific	   	   describing	   	   a	   major	   susceptibility	   to	   autoimmune	   disease	  (thyroid	   disease,	   insulin-­‐dependent	   diabetes).	   3.	   IBD-­‐related	   aggravations	   due	   to	  metabolic	  complications	  (thromboembolic	  events,	  osteoporosis).	  	  
1.3.3.	  Disease	  complications	  Surgery	   is	   not	   considered	   a	   final	   curing	   option	   in	   CD	   and	   should	   be	   used	   only	   in	   specific	  situations	   such	  as	  abscesses,	   internal	   fistulas	   that	  are	  not	   responding	   to	  medical	   treatment,	  fibrostenotic	   strictures,	   bowel	   obstruction	   or	   cancer	   (21).	   Regarding	   UC	   about	   20-­‐30%	   of	  patients	   need	   surgery	   during	   their	   lifetime.	   Urgent	   surgery	   is	   indicated	   when	   a	   life-­‐threatening	   complication	   appear	   for	   example	   fulminant	   colitis.	   An	   elective	   procedure	   is	  considered	  when	  the	  disease	   is	  refractory	  or	  a	  colorectal	  cancer	   is	  discovered	   (17).	  Screening	  for	   disease	   complications	   such	   as	   colorectal	   cancer,	   abscess,	   malnutrition,	   osteoporosis,	  anemia,	  opportunistic	  infections	  and	  monitoring	  for	  medication	  adverse	  effects	  is	  required	  to	  optimizing	  the	  medications.	  	  	  
1.4	  Drug	  management	  Since	   the	   exact	  mechanisms	   underlying	   IBD	   are	   not	   identified,	   a	   curative	   therapy	   does	   not	  exist	   (13).	   Various	   drugs	   exist	   to	   induce	   and	   maintain	   disease	   remission.	   The	   mainstay	   of	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pharmacological	   therapy	   is	   described	   in	   table	  2.	  Apart	   from	   the	  pharmacological	   control	   of	  disease,	   management	   of	   IBD	   patients	   also	   includes	   general	   measures.	   These	   include:	  improving	   patient	   adherence	   to	   medication,	   smoking	   cessation,	   avoidance	   of	   exacerbating	  medications	   such	   as	   non	   steroidal	   anti-­‐inflammatory	   medication,	   oral	   contraceptives	   and	  antibiotic.	  	  Table	  2:	  Pharmacological	  therapy	  for	  IBD.	  	  
Drug	   Commercial	  name	   Characteristics	  
Mesalazine	  
=	   5-­‐aminosalicylic	   acid	  
(5-­‐ASA)	   Asacol®	  Asazine®	  	  Pentasa®	  	  
Salofalk®	  	  
The	   derivatives	   of	   aminosalicylate	   drugs	   are	  widely	   used.	   Especially	   in	   cases	   of	   mild	   or	  moderate	  severity	  of	  UC	  (19,	  32)	  Side	  effects:	  Rare.	  Headache,	  nausea,	  rash,	  skin,	  thrombocytopenia	   (36),	   interstitial	   nephritis	   or	  nephrotic	   syndrome	   (32),pancreatitis,	  hepatitis,(32)	   bloody	   diarrhea	   (not	   to	   be	  confused	  with	  disease	  worsening)	  (36)	  
Azathioprine	   and	   6-­‐
mercaptopurine	  (Immununomodulateurs)	   Imurek®,	  Purinéthol®	   Side	   effects:	   hematological,	   hypersensitivity	  reactions,	   infections,	   pancreatitis,	  gastrointestinal-­‐intolerance.	   Mild	   increased	  risk	  of	  lymphoma.	  
Methotrexate	  (antimetabolite	   and	  antifolate	  drug)	   Methoject®	   Side	  effects:	  hepatotoxicity,	  pulmonary	  fibrosis,	  and	  myelosuppression,	   contraindicated	  during	  pregnancy	   and	   a	   reliable	   method	   of	   birth	  control	  should	  be	  used.	  	  








Used	  for	  induction	  and	  maintenance	  (19)	  .	  Side	  effects:	  see	  body	  of	  the	  manuscript	  Contraindications:	  -­‐Patients	  suffering	  form	  an	  active	  or	  untreated	  	  -­‐Tuberculosis	  (TB).	  	  -­‐Current	  or	  recent	  neoplasia.	  	  -­‐Sepsis.	  	  -­‐Optic	  neuritis.	  	  -­‐Infusion	  reaction(19)	  	  -­‐	  Severe	  congestive	  heart	  failure	  (7)	  	  
1.4.1	  Anti	  TNF-­‐α	  treatment	  Anti-­‐TNF-­‐α	   therapies	   are	   central	   in	   current	   treatment	   strategies	   for	   IBD.	   However	   loss	   of	  response,	  intolerance	  and	  immunogenicity	  are	  limiting	  factors.	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Over	  the	  past	  15	  years,	  with	  the	  introduction	  of	  anti-­‐TNF,	  treatment	  strategies	  for	  CD	  and	  UC	  have	   changed	   dramatically	   (37).	   Additionally	   treatment	   goals	   have	   also	   shifted	   to	   include	  mucosal	   healing,	   as	   well	   as	   clinical	   remission,	   reduction	   in	   risk	   of	   neoplasia,	   reduction	   in	  hospitalization	  and	  surgery	  and	  improvement	  in	  quality	  of	  life	  (38).	  In	  Western	  Europe	  about	  60%	   of	   patients	   with	   CD	   are	   treated	   with	   immunomodulators	   and	   30%	   with	   biological	  therapies	  (39).	  Immunomodulators	   such	   as	   azathioprine,	  mercaptopurine	   or	  methotrexate	   act	   in	   a	   generic	  and	  non-­‐specific	  way.	  On	  the	  contrary,	  biologics	  are	  highly	  engineered	  proteins,	  which	  target	  specific	  inflammatory	  cytokines	  that	  are	  involved	  in	  the	  pathogenesis	  of	  the	  disease	  (19).	  The	  main	  indication	  for	  TNF	  inhibitors	  is	  active	  moderate	  to	  severe	  CD	  or	  UC,	  which	  did	  not	  respond	  to	   first	   line	   therapy	  and	  are	  refractory	  or	  cortico-­‐dependent.	   In	  case	  of	  moderately	  active	  disease	  and	  corticosteroid/immunosupressor	  refractory,	  anti-­‐TNF-­‐α	  is	  an	  appropriate	  option	   (40).	  Also	   in	  severe	  colitis	   they	  show	  an	   important	  role.	  The	  efficacy	   for	   induction	   for	  IFX	  is	  around	  60-­‐70%	  and	  a	  remission	  rate	  of	  about	  30-­‐40%	  (37,	  41,	  42).	  	  Indications	   for	   TNF	   inhibitors	   in	   CD	   include	  moderate	   to	   severe	   active	   ileal	   and/or	   colonic	  disease,	  when	  the	  patient	  is	  steroid-­‐refractory,	  -­‐dependent,	  or	  -­‐intolerant..	  TNF	  inhibitors	  are	  also	  indicated	  in	  case	  of	  fistulizing	  disease	  (41).	  Adverse	   effect	   of	   anti-­‐TNF-­‐α	   therapy	   exists,	   such	   as	   anaphylactic	   reactions	   and	   infections.	  Rare	  but	  serious	  cases	  of,	  melanoma	  skin	  cancer,	  drug	  induced	  lupus	  and	  psoriasis	  have	  been	  noted(43).	  However	  hazard	  ratio	  for	  serious	  infection	  for	  infliximab	  is	  1.77,	  but	  prednisone	  is	  associated	  with	  double	  of	  risk	  of	  serious	  infection(19).	  Following	  drugs	  are	  available	  
Infliximab	   is	  a	  chimeric	  monoclonal	   IgG1	  antibody	  (75%	  human,	  25%	  murine),	  which	  binds	  soluble	  and	  cell-­‐surface	  TNF-­‐α	  (41,	  44)	  .	  It	  is	  administered	  intravenously:	  5mg/kg	  at	  weeks	  (0,	  2,	  6)	  for	  the	  induction	  and	  every	  8	  weeks	  for	  the	  maintaining	  dose	  (7).	  	  
Adalimumab	   is	   a	   fully	   humanized	   monoclonal	   IgG1	   antibody	   (41).	   It	   is	   administrated	  subcutaneously;	  160	  mg	  at	  week	  0	  and	  then	  80	  at	  week	  2	  and	  finally	  40mg	  every	  second	  week.	  	  
Certolizumab	   pegol	   is	   an	   antibody	   Fab’	   fragment	   conjugated	   with	   a	   polyethylene	   glycol	  molecule.	   It	   is	  administrated	  subcutaneously;	   the	   induction	  dose	   is	  400	  mg	  at	  weeks	  (0,2,4)	  then	  every	  4	  weeks	  (7).	  Certolizumab	  pegol	  is	  registered	  in	  Switzerland	  (41).	  We	  were	  not	  able	  to	  find	  any	  recommended	  blood	  level	  for	  this	  agent.	  Infliximab	  and	  adalimumab	  are	  effective	  for	  induction	  and	  maintenance	  of	  remission	  in	  both	  CD	  and	  UC	  while	  certolizumab	  pegol	  has	  been	  approved	  for	  use	  in	  CD	  patients	  (41,	  45).	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  Figure	  3:	  Mode	  of	  action	  of	  anti-­‐TNFα	  agents	  (7).	  	  
	  	  Figure	  3.	  Anti-­‐TNF-­‐α agents	  bind	  the	  precursor	  transmembrane	  TNF-­‐ α and	  the	  soluble	  TNF-­‐
α, neutralizing	  the	  pro-­‐inflammatory	  signaling	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1.4.2	  Loss	  of	  response	  to	  anti	  TNF-­‐α	  agents	  and	  appropriate	  strategies	  Despite	   significant	   response	   and	   remission	   rates	   with	   anti-­‐TNF-­‐α,	   clinicians	   are	   often	  confronted	   with	   primary	   and	   secondary	   loss	   of	   response	   or	   side	   effect	   during	   long-­‐term	  therapy.	  Therefore,	  my	  master	  project	  is	  focused	  on	  therapeutic	  drug	  monitoring	  of	  anti	  TNF-­‐α	  agents	  to	  optimize	  their	  use	  in	  IBD	  patients.	  Primary	  non-­‐response	   is	   observed	  when	  no	   clinically	   relevant	   response	   after	   the	   induction	  can	   be	   observed.	   Secondary	   non-­‐response	   is	   observed	   when	   the	   clinically	   response	   is	   not	  sustained	   for	   more	   than	   12	   months.	   Therapeutic	   drug	   monitoring	   (TDM)	   might	   offer	   a	  rational	  approach	  in	  case	  of	  secondary	  non-­‐response	  (37).	  Monoclonal	  antibodies	  like	  biological	  drugs	  act	  like	  foreign	  antigens	  for	  the	  humoral	  immune	  system,	   which	   generate	   high	   affinity	   antibodies	   against	   biological	   drugs.	   These	   specific	  antibodies	  may	  reduce	  the	  efficacy	  of	  TNF-­‐α	  antagonists	  (37).	  	  Lose	  of	  response	  occurs	  approximately	  in	  40%	  of	  the	  patients,	  who	  initially	  respond	  to	  TNF-­‐α	  antagonists	  (46).	  In	   case	   of	   a	   primary	   non-­‐response	   anti-­‐TNF-­‐therapy	   is	   considered	   non-­‐effective	   in	   about	   a	  third	  of	  patients	  for	  this	  specific	  case.	  A	  non-­‐TNF	  pathological	  mechanism	  can	  be	  considered,	  so	  switching	  to	  another	  anti-­‐TNF	  is	  not	  advisable	  (10).	  	  	  There	   are	   emerging	   data	   from	   the	   literature	   suggesting	   that	   infliximab	   trough	   levels	  might	  help	  clinicians	  tailoring	  therapy	  and	  overcome	  on-­‐treatment	  IBD	  flares.	  In	  fact	  measurement	  of	  serum	  drug	  and	  anti-­‐drug-­‐antibody	  (ADA)	  concentrations	  has	  the	  potential	  to	  guide	  health	  professional’s	   decision,	   optimize	   treatment	   and	   reduce	   healthcare	   costs	   (47).	   For	   IFX	   a	  reasonable	   target	   of	   trough	   level	   for	   a	   positive	   predictive	   value	   and	   sustained	   remission	   is	  3.0-­‐7.0	  microgram/ml	  (47).	  There	  are	  more	  limited	  data	  for	  Adalimumab,	  but	  they	  indicate	  that	  a	  concentration	  less	  than	  5	  micrograms/mL	  is	  seen	  in	  patients	  with	  active	  disease	  (47)	  The	  clinical	  presentation	  of	  ADAs	  related	  side	  effects	  of	  anti-­‐TNF	  includes	  either	  erythemas	  at	  the	   injection	  site	  or	  anaphylactoid	  reactions	  with	  hypotension,	  dyspnea	  and	  flushing.	  Serum	  sickness	  with	  fever,	  rash	  or	  arthralgia	  may	  also	  occur	  (48).	  ADAs	   increase	   drug	   clearance,	   negatively	   influence	   the	   pharmacokinetics	   (PK)	   of	   anti-­‐TNF	  and	  therefore	  the	  clinical	  outcome	  (37).	  It	  is	  true,	  however,	  that	  ADAs	  are	  not	  the	  only	  element	  that	  increase	  the	  clearance	  of	  biologics.	  In	  fact	  low	  albumin	  levels	  and	  male	  sex	  increase	  the	  clearance	  too	  (44).	  	  Higher	  Anti-­‐TNF-­‐alpha	   levels,	  more	  specifically	  higher	   IFX	   levels	  are	  associated	  with	  higher	  rate	  of	  clinical	  remission.	  Conversely,	  the	  presence	  of	  ADA	  has	  been	  linked	  to	  poorer	  disease	  outcome	  (49):	  an	  8	  microgram/mL	  concentration	  of	  ADA	  or	  less	  is	  associated	  with	  few	  relapses	  than	  higher	  concentration	  (47).	  ELISA	  (enzyme-­‐linked	  immunosorbent	  assay),	  HMSA	  (homogenous	  mobility	  shift	  assay),	  RIA	  (radioimmunoassay)	  are	  the	  most	  commonly	  used	  methods	  to	  measure	  trough	  level	  drug	  and	  ADA	  (47).	  In	  this	  study	  anti-­‐TNF-­‐a	  and	  ADA	  are	  measured	  using	  a	  commercially	  available	  ELISA.	  Trough	   level	   refers	   to	   the	   lowest	   point	   to	  which	   levels	   of	   a	   drug	   fall	   in	   the	   blood	   between	  doses.	   In	  order	  to	  have	  an	  accurate	  estimation,	  trough	  level	  should	  be	  measured	  just	  before	  the	  administration	  of	  the	  next	  dose.	  Following	   preliminary	   consensus	   has	   been	   recommended	   for	   cases	   with	   secondary	   loss	   of	  response	  (47):	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  Table	  3:	  Adapted	  proposed	  strategy	  for	  tailored	  therapy	  with	  anti	  TNF-­‐α	  agents	  (47).	  	   	   ADA-­‐negative	   ADA-­‐positive	  
Anti-­‐TNF	  <	  threshold	   Increase	  dosage	   Switch	  to	  another	  anti	  TNF-­‐α	  
Anti-­‐	  TNF	  ≥	  threshold	  
	  
Change	  of	  class	  of	  drugs	  Example	  ustekinumab	  
Stelara®	   Monitor	   the	   activity	   of	   the	  disease	  	  	  The	  most	  appropriate	   strategy	  varies	   from	  patient	   to	  patient,	  but	  also	   from	  availability	  and	  cost.	  If	  the	  situation	  permits,	  increasing	  the	  frequency	  or	  increasing	  the	  dose	  of	  biological	  drugs	  is	  an	   appropriate	   strategy	   before	   switching	   to	   another	   anti-­‐TNF-­‐α.	   In	   addition	   we	   have	   to	  remember	  that	  switching	  is	  an	  effective	  strategy,	  but	  can	  reduce	  therapeutics	  options	  the	  use	  of	  the	  former	  drug	  in	  the	  future	  (41).	  Using	  IFX	  as	  an	  example:	  if	  the	  infliximab	  concentration	  is	  subtherapeutic	  and	  ADA	  level	  are	  low,	  doctors	  have	   the	   interest	  of	   increasing	   the	  dosage	  of	   infliximab.	  On	   the	   contrary	   if	   the	  patients	  have	   low	  concentration	  and	  detectable	  ADA	  switching	  to	  another	  TNF-­‐α	  antagonist	  result	  with	  better	  outcomes.	  When	  the	  situation	  is	  a	  little	  be	  more	  complicated;	  trough	  level	  is	  high,	   but	   ADA	   also	   high,	   three	   options	   are	   available	   change	   of	   TNF	   inhibitor,	   addiction	   of	  immunosuppressant	   or	   change	   of	   class	   (44).	   In	   patients	   with	   supratherapeutic	   drug	  concentration,	  who	  are	  feeling	  well,	  the	  possibility	  to	  reduce	  de	  dosage	  it	  is	  also	  possible	  (47).	  During	  the	  use	  of	  biological	  drugs	  injection-­‐site	  reaction	  and	  anaphylactic	  reactions	  have	  been	  reported.	  In	  this	  cases	  switching	  to	  another	  biological	  drugs	  is	  needed	  (41).	  
1.4.3	  New	  treatment	  approaches	  As	   mentioned	   earlier,	   although	   efficient,	   anti-­‐TNF	   agents	   fail	   to	   offer	   any	   benefit	   in	   a	  significant	   proportion	   of	   patients.	   Over	   the	   past	   years,	   several	   novel	   pathophysiologic	  mechanisms	  of	  disease	  have	  been	  targeted	  for	  drug	  interventions.	  Overall,	  current	  treatment	  strategies	  target	  lymphocyte	  trafficking	  through	  integrin	  blockade	  (vedolizumab)	  or	  alternate	  cytokines	  such	  as	  IL12	  or	  IL-­‐23	  (ustekinumab).	  	  (21).	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2.	  Study	  aims	  1. To	  evaluate	  the	  indications	  for	  trough	  anti-­‐TNF-­‐α	  and	  ADA	  serum	  testing	  2. 	  To	  determine	  the	  prevalence	  of	  ADA	  and	  the	  therapeutic	  range	  of	  anti-­‐TNF	  trough	   level	  measures	  3. 	  To	   assess	   the	   clinical	   impact	   of	   trough	   anti-­‐TNF-­‐α	   and	   ADA	   serum	   levels	   on	   routine	  management	  of	  IBD	  patients	  
3.	  Study	  Design	  This	  is	  a	  retrospective	  study	  of	  anti-­‐TNF	  trough	  level	  and	  ADA	  serum	  determinations	  in	  IBD	  patients	   receiving	   anti-­‐TNF	   agents.	   We	   included	   all	   therapeutic	   drug	   monitoring	  measurements	   performed	   from	   05.03.2013	   to	   23.04.2014.	   	   A	   total	   of	   70	   patients	   where	  included	   between	   two	   tertiary	   referral	   centers:	   clinic	   La	   Source	   and	   the	   service	   of	  Gastroenterology	  of	  the	  CHUV.	  	  Patients	   have	   been	   identified	   from	   blood	   samples	   (marked	   as	   “IBD”)	   sent	   to	   the	   Service	  d’immunologie	   et	   d’allergologie,	   CHUV,	   for	   measurement	   of	   anti-­‐TNF-­‐α	   and	   ADA	  concentrations.	   A	   chart	   review	   to	   evaluate	   the	   indications	   for	   trough	   levels	   and	   clinical	  management	   has	   been	  performed.	   The	  whole	   process	   of	   data	   collection	   and	   analyzing	   data	  has	  been	  approved	  by	   the	  scientific	  committee	  of	   the	  Swiss	   IBD	  Cohort	  Study	  (SIBDCS)	  and	  also	  approved	  by	  our	  local	  ethics	  committee	  (VD).	  	  Disease	  phenotype	  has	  been	  classified	  according	  to	  the	  Montreal	  classification	  as	  mentioned	  in	  Table	  4.	  	  Table	  4:	  Montreal	  classification(50)	  
	  	  
IBD	   Ulcerative	  colitis	  	  (UC)	   Crohn’s	  disease	  (CD)	  
Localization	   Montréal	  Classification	  Inflammation	  limited	  to	  the	  rectum	  (E1),	  Inflammation	  limited	  to	  the	  splenic	  flexure	  (E2),	  Inflammation	  extends	  to	  the	  proximal	  splenic	  flexure	  (E3)	  
Montréal	  Classification	  Terminal	  ileum	  (L1),	  Colon	  (L2),	  Ileocolon	  (L3),	  Upper	  GI	  tract	  (L4),	  Upper	  GI	  tract	  +	  distal	  disease	  (L4+L3)	  
Age	   Montréal	  Classification	  <16	  years	  (A1),	  16-­‐40	  y	  (A2),	  >40y	  (A3)	   Montréal	  Classification	  <16	  years	  (A1),	  17-­‐40	  y	  (A2),	  >40y	  (A3)	  
Behavior	   and	  
severity	  	  
S0	  	  Clinical	  remission	  S1	  Mild	  UC	  S2	  	  Moderate	  UC	  S3	  Severe	  UC	  	  
Montréal	  phenotype	  classification:	  non-­‐stricturing	  non-­‐penetrating	  (B1)	  or	  stricturing	  (B2)	  and	  penetrating	  (B3)	  Perianal	  fistulae	  and	  abscesses	  (indicated	  with	  p)	  are	  no	  longer	  included	  in	  penetrating	  phenotype.	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3.1	  Inclusion	  criteria	  1.	  Adult	  patients	  affected	  with	  CD	  or	  UC.	  2.	  Patients	  for	  whom	  an	  anti-­‐TNF-­‐α	  trough	  level	  and	  /	  or	  anti-­‐	  drug	  antibodies	  were	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  performed	  at	  CHUV.	  3.	  Current	  treatment	  by	  anti-­‐TNF-­‐	  α	  agents.	  
3.2	  Exclusion	  criteria	  1.Not	  IBD	  diagnosed.	  2.	  Adults	  patients	   suffering	   from	  another	  chronic	   inflammatory	  disease	   requiring	   treatment	  with	  anti-­‐TNF-­‐α	  such	  as	  rheumatoid	  arthritis.	  3.	  Treatment	  with	  anti-­‐TNF-­‐α	  interrupted	  before	  the	  assays.	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4.	  Results	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4.2	  Clinical	  demographic	  The	   characteristics	   of	   the	   70	   patients	   appear	   in	   table	   5.	   	   There	   were	   no	   male	   or	   female	  predominance	  and	  average	  age	  was	  40	  years.	  Most	  tests	  were	  performed	  for	  Crohn’s	  disease	  (73%).	  	  Disease	  distribution	  was	  pretty	  homogenous	  with	  a	  majority	  of	  CD	  patients	  having	  an	  L3	  (ileo-­‐colonic)	  phenotype.	  A	  large	  subset	  of	  our	  patients	  had	  been	  previously	  managed	  with	  immunomodulators	  (54.29%).	  However,	  few	  cases	  were	  on	  combination	  therapy	  (10%).	  The	  mean	  time	  to	  initial	  testing	  and	  start	  of	  the	  biological	  was	  19	  months.	  The	  mean	  time	  between	  the	  diagnosis	  and	  testing	  was	  72	  months.	  	  Table	  5:	  Patients	  characteristics.	  	  
Patients	  characteristics	  n=70	  Female/male	  (%	  female)	   33/37(47%)	  Age	  average	  (range,	  SD)	   40	  (20-­‐77;	  14)	  UC/CD	  (%CD)	   19/51	  (73%)	  Montréal	  distribution	  UC	  E1	   0	  (0%)	  E2	   5	  (26.32%)	  E3	   5	  (26.32%)	  Not	  defined	   9	  (47.36%)	  CD	  L1	   13(25.49%)	  L2	   9	  (17.65%)	  L3	   20	  (39.22%)	  L4	   1	  (1.96%)	  Not	  defined	   8	  (15.69%)	  Smoking	  status	  Current	  smoker	   19	  (27.14%)	  Non	  smoker	   28	  Undefined	   23	  Timing	  of	  assay	  determinations	  Time	  elapsed	  between	  start	  of	  biological	  drugs	  and	  first	  assay	  (months,	  range)	  	  
19	  (1-­‐104)	  
Time	  elapsed	  between	  date	  of	  diagnosis	  of	  IBD	  and	  first	  assay	  (months)	  	  
72	  (5-­‐404)	  
Concomitant	  immunomodulators	  Never	  use	  	   2	  (2.86%)	  Current	  AZA	   5	  (7.14%)	  Current	  6-­‐MP	   2	  (2.86%)	  Current	  methotrexate	   0	  Prior	  use	  of	  immunomodulator	   38	  (54.29%)	  Not	  defined	   23	  (32.86%)	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3.3 Indication	  The	  great	  majority	  (79%)	  of	  the	  determinations	  were	  performed	  as	  “medical	  follow	  up”.	  The	  indication	  pre-­‐treatment	  evaluation	  was	  actively	  searched,	  but	  no	  clinicians	  performed	  the	  determination	  as	  “pre-­‐treatment	  evaluation”.	  The	  main	  indication	  for	  testing	  was	  “medical	  follow	  up”.	  Therapeutic	  failure	  (7%)	  and	  possible	  autoimmune	  /	  delayed	  hypersensitivity	  reaction	  (5%)	  were	  further	  relevant	  indications	  (Figure	  5).	  	  Figure	  5:	  Indication	  for	  trough	  level	  and	  ADA	  measurement	  (n=117	  blood	  tests	  performed).	  
	  	  	   	  
79%	  
6%	  5%	  
3%	   7%	  
Indication	  for	  trough	  level	  and	  ADA	  
measurement	  (n=117	  blood	  tests	  
performed).	  	  	   medical	  follow-­‐up	  
therapeutic	  failure	  
during	  induction	  
infusion	  reaction/intolerance	  not	  detined	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4.5	  Clinical	  approach	  Figure	  7	  shows	  the	  clinical	  management	  after	  all	  assays.	  Of	  117	  total	  tests	  assessed	  the	  results	  impacted	  treatment	  decisions	  in	  approximately	  40%	  of	  the	  cases.	  	  	  Figure	  7:	  Clinical	  management	  after	  all	  assays.	  Number	  of	  assays	  performed	  (n=117).	  
	  	   	  
61%	  11%	  
8%	  
2%	  2%	   5%	  
8%	   3%	  
Clinical	  management	  after	  all	  assays.	  
Number	  of	  assays	  performed	  (n=117)	  	  no	  chage	  increase	  dosage	  or	  frequency	  switch	  to	  another	  anti-­‐TNF	  change	  of	  class	  addition	  of	  immunomodulator	  stop	  of	  the	  treatement	  lower	  the	  dosage	  not	  available	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Figure	  8:	  Clinical	  management	  
	  	  Figure	  8	  shows	  the	  management	  following	  the	  first	  determination	  trough	  level	  of	  anti-­‐TNFα	  and	  ADA	  	  This	   figure	   depicts	   that	   anti-­‐TNFα	   trough	   level	   and	   ADA	   determination	  was	   followed	   by	   a	  change	  in	  management	  in	  approximately	  one	  third	  of	  the	  cases.	  	  In	  14	  patients	  (section	  A)	  without	  ADA,	  the	  trough	  level	  was	  subtherapeutic.	  In	  no	  more	  than	  5	   of	   these	   patients	   the	   anti-­‐TNFα	  dose	   or	   frequency	  were	   increased.	   In	   the	  majority	   of	   the	  patients	  the	  management	  was	  not	  adjusted	  (likely	  because	  that	  disease	  was	  not	  active).	  	  7	  out	  of	  11	  patients	  (section	  B)	  were	  found	  to	  have	  ADA	  and	  subtherapeutic	  trough	   levels	  the	  management	  anti-­‐TNFα	  was	  discontinued	  and	  replaced	  by	  another	  one.	  In	  30	  cases	  (section	  C)	  without	  ADA	  the	   through	   level	  was	  within	   therapeutic	  ranges.	   In	  24	  (80%)	  of	  these	  patients	  the	  management	  was	  not	  modified.	  In	  12	  (Section	  D)	  patients	  the	  anti-­‐TNFα	  trough	  level	  was	  supratherapeutic.	  In	  no	  more	  than	  3	  of	  these	  patients	  the	  dosage	  was	  reduced.	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5.Discussion	  Inflammatory	   bowel	   diseases	   have	   an	   important	   impact	   on	   the	   quality	   of	   life	   of	   affected	  patients	   and	   the	   increasing	   number	   of	   cases	   worldwide	   is	   a	   growing	   concern.	   The	  management	   of	   inflammatory	   bowel	   disease	   patients	  who	   are	   refractory	   both	   to	   treatment	  with	   first-­‐line	   agents	   such	   as	   glucocorticoids,	   5-­‐aminosalicylates	   or	   antibiotics	   as	   well	   to	  second-­‐line	  agents	  such	  as	  azathioprine	  and	  methotrexate	  is	  well	  recognized	  and	  challenging.	  	  Well-­‐controlled	   trials	   support	   the	   use	   of	   anti-­‐TNF-­‐α	   in	   the	   treatment	   of	   these	   conditions.	  These	  agents	  are	  typically	  highly	  effective	  for	  induction	  and	  maintenance	  of	  clinical	  remission.	  However,	   not	   all	   patients	   respond	   and	   a	   proportion	   of	   them	   lose	   response	   over	   time.	   Low	  trough	  circulating	  levels	  and	  the	  development	  of	  antibodies	  to	  anti-­‐TNFα	  drugs	  are	  the	  main	  mechanisms	  that	  have	  been	  proposed	  to	  explain	  why	  some	  patients	  do	  not	  respond	  to	  these	  drugs.	  	  Available	   studies	   indicate	   that	   measuring	   drug	   and	   ADA	   levels	   can	   guide	   the	   appropriate	  intervention	  and	  results	  in	  more	  efficient	  use	  of	  the	  drugs	  (29,	  51-­‐53).	  	  a)	  The	  data	  collected	  by	  the	  group	  of	  Rochester	  suggest	  that	  measuring	  drug	  and	  ADA	  levels	  impacts	   treatment	   decision	   in	   approximately	   three	   quarters	   of	   155	   patients	   with	   loss	   of	  response	  or	  partial	  response	  after	  initiation	  of	  infliximab	  (52).	  	  b)	   The	   report	   by	   a	   French	   group	   included	   82	   IBD	   patients	   having	   a	   disease	   flare	  while	   on	  treatment	  with	  adalimumab.	  The	  results	   indicate	  that	  assessing	  drug	  and	  ADA	  levels	  has	  an	  impact	  on	  management	  in	  approximately	  two	  thirds	  of	  the	  cases	  (53).	  	  c)	  A	  retrospective	  analysis	  including	  a	  total	  of	  247	  pediatric	  and	  adult	  patients	  with	  IBD	  while	  on	   treatment	   with	   infliximab	   or	   adalimumab	   was	   performed	   in	   Israel.	   The	   authors	   of	   the	  report	   noted	   that	   measurement	   of	   anti-­‐TNF	   drug	   level	   and	   ADA	   is	   useful	   for	   guiding	   the	  management	   of	  more	   than	   two	   thirds	   of	   patients	  with	   a	   loss	   of	   response	   to	   the	  mentioned	  biological	  (29).	  d)	  A	  Belgian	  study	  including	  263	  IBD-­‐patients	  demonstrated	  that	  targeting	  infliximab	  trough	  level	  to	  3–7	  mg/mL	  results	  in	  a	  more	  efficient	  use	  of	  the	  drug	  (51).	  	  Mean	   age	   was	   very	   similar	   in	   the	   four	   (29,	   51-­‐53)	   aforementioned	   studies	   and	   in	   our	   cases	  (approximately	  40	  years).	  The	  female	  to	  male	  ratio	  was	  approximately	  1.3	  in	  two	  studies	  (52),	  (53),	  approximately	  1.0	  in	  the	  other	  two	  (29),(51)	  and	  1.1	  in	  our	  experience.	  Our	  study,	  performed	  in	   two	   tertiary	   referral	   centers,	   represents	   the	   first	   Swiss	   analysis	   addressing	   the	   clinical	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utility	   of	   the	   determination	   of	   anti	   TNF-­‐α	   trough	   level	   and	   ADA	   in	   patients	  with	   IBD.	   	   The	  majority	   of	   our	   patients	   were	   managed	   exclusively	   with	   biological,	   but	   without	  immunomodulators.	  	  The	  patients	  were	  tested,	  on	  average,	  approximately	  one	  year	  and	  a	  half	  after	  initiation	  of	  biological	  treatment.	  	  The	  great	  majority	  of	  tests	  (approximately	  80%)	  were	  performed,	   similar	   to	   the	  Belgian	   study	   (51),	   for	  medical	   follow	  up.	  This	   fact	   likely	   indicates	  that	  many	  patients	  were	   on	  maintenance	   therapy.	  Although	  our	   study	  was	  not	   designed	   to	  measure	   disease	   activity	   at	   the	   time	   of	   trough	   level	   determination,	   we	   assume	   that	   most	  patients	  in	  this	  category	  were	  probably	  asymptomatic	  in	  the	  maintenance	  phase.	  	  The	  results	  indicate	  that	  clinicians	  consider	  these	  determinations	  useful	  and	  trustful,	  as	  indicated	  by	  the	  fact	  that	  anti	  TNF-­‐α	  dosing	  was	  often	  adapted	  according	  to	  available	  recommendations	  (more	  frequently	   in	   cases	   with	   subtherapeutic	   trough	   level	   and	   ADA-­‐positive	   cases	   than	   in	   cases	  with	  supratherapeutic	   trough	   level)	   (47).	  The	  apparent	  discrepancies	  with	   recommendations	  noted	   in	   a	   large	   minority	   of	   cases	   likely	   result	   from	   the	   fact	   that	   clinicians’	   decisions	   are	  mainly	  based	  on	   IBD	  disease	  activity,	  and	  possibly	   is	  also	   influenced	  by	  co-­‐morbidities,	  and	  socio-­‐economical	  factors.	  We	  feel	  that	  after	  testing	  drug	  and	  ADA	  levels,	  clinicians	  may	  gain	  a	  sense	   of	   saliency	   in	   relation	   to	   decision-­‐making	   not	   only	   in	   cases	   with	   poor	   response	   to	  biologicals	  but	  even	  in	  stable	  cases.	  Two	   IBD-­‐cases	   included	   in	   this	   survey	   deserve	   particular	   attention	   and	   may	   be	   used	   to	  further	  address	  the	  issue	  of	  monitoring	  anti-­‐TNF-­‐α	  through	  level	  and	  ADA.	  	  A	   non-­‐smoking	   24-­‐year	   old	   woman	  was	   found	   to	   suffer	   from	   CD	   L3.	   The	   disease	   failed	   to	  remit	  on	  IFX-­‐treatment	  with	  satisfactory	  trough	  levels	  (>8	  µg/ml)	  and	  absent	  ADA	  and	  later	  on	  adalimumab-­‐treatment	  again	  with	  satisfactory	  trough	  levels	  (>8	  µg/ml)	  and	  absent	  ADA.	  We	  feel	  that	  management	  with	  compounds	  with	  different	  mode	  of	  action	  such	  as	  natalizumab,	  alicaforsen	  or	  vedolizumab	  might	  be	  prescribed	  in	  this	  intriguing	  case.	  A	   non-­‐smoking	   46-­‐year	   old	   man	   with	   UC	   E2	   on	   long-­‐term	   treatment	   with	   IFX	   suddenly	  developed	  severe	  edema	  and	  arthritis	   immediately	  after	  administering	   this	  biological	  agent.	  In	   retrospect	   the	   patient	   was	   found	   to	   have	   trough	   anti-­‐TNF-­‐α	   level	   <0.3	   µg/ml	   and	   ADA	  strongly	   positive.	   Awareness	   of	   ADA	   level	   might	   have	   prevented	   the	   potentially	   life	  threatening	  reaction.	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Some	  limitations	  in	  this	  study	  deserve	  mention.	  The	  major	  limitation	  of	  the	  study	  resides	  in	  its	  retrospective	  nature.	  Consequently,	  no	  standardized	  scoring	  system	  was	  used	  to	  correlate	  the	   disease	   activity	   with	   the	   circulating	   anti	   TNF-­‐α	   through	   level.	   Furthermore,	   we	   were	  sometimes	   not	   able	   to	   reconstruct	   the	   reasons	   underlying	   some	   clinical	   decisions.	   For	  example,	   in	   some	   situations,	   clinicians	   do	   not	   increase	   the	   	   dosage	   in	   patients	   with	  subtherapeutic	  trough	  level	  because	  of	  a	  low	  disease	  activity,	  showing	  that	  doctors	  have	  other	  influences	  on	  the	  decisions	  making	  processes.	  	  Moreover,	  the	  number	  of	  patients	  included	  in	  the	  analysis	  was	  rather	  low.	  Finally,	  our	  results,	  which	  were	  collected	  in	  two	  tertiary	  referral	  centers,	   might	   perhaps	   not	   be	   extrapolated	   for	   cases	   concomitantly	   treated	   with	  immunomodulators.	  The	  results	  of	  our	  study,	  taken	  together	  with	  those	  of	  the	  literature	  (29,	  51-­‐53),	  might	  prompt	  to	  recommend	  the	  determination	  of	  anti-­‐TNF-­‐α	  trough	  and	  ADA	  level	  in	  IBD-­‐patients.	  Based	  on	  those	   observations,	   we	   propose	   the	   following	   attitude	   with	   respect	   to	   on-­‐treatment	  monitoring:	  	  a)	   Increasing	   the	   dose	   of	   anti-­‐TNF-­‐α	   therapy	   is	   advised	   in	   patients	  with	   anti-­‐TNF	  α	   trough	  levels	  <3	  µg/ml	  and	  without	  ADA	  (an	  perhaps	  also	  in	  patients	  with	  levels	  <5	  µg/ml)	  b)	   Decreasing	   the	   dose	   of	   anti-­‐TNF-­‐α	  might	   be	   recommended	   in	   patients	   in	   remission	   and	  with	  drug	  level	  >8	  µg/ml.	  c)	  Patients	  developing	  high	  levels	  of	  ADA	  are	  less	  likely	  to	  benefit	  from	  dose	  intensification.	  	  d)	  In	  patients	  with	  persisting	  disease	  activity	  despite	  therapeutic	  drug	  level	  near	  to	  8	  µg/ml	  and	  no	  anti-­‐drug	  antibodies	  (see	  case	  presented	  below),	  it	  is	  appropriate	  to	  switch	  to	  a	  drug	  with	  a	  different	  mode	  of	  action.	  e)	   Patients	   with	   very	   high	   levels	   of	   ADA	   are	   at	   high	   risk	   (like	   the	   male	   subject	   presented	  below)	  of	  severe	  allergic	  reactions.	  	  
6.	  Conclusion	  	  The	  TDM	  suggested	  in	  this	  survey	  is	  expected	  to	  avoid	  repeated	  bouts	  of	  IBD.	  In	  particular,	  it	  is	  likely	  that	  TDM	  will	  soon	  evolve	  into	  a	  3-­‐tiered	  approach:	  it	  will	  first	  guide	  the	  induction;	  it	  will	   subsequently	   dictate	   dose	   titration	   to	   prevent	   disease	   flares;	   and	   finally	   it	   will	   guide	  interventions	   for	  cases	  with	   loss	  of	  response	  to	  biologicals.	  However,	  some	  knowledge	  gaps	  still	   need	   to	   be	   addressed	   to	   confirm	   this	   strategy.	   Specifically,	   future	   research	   needs	   to	  explore	  dose	  optimization	  protocols,	  preferably	  using	  more	  sensitive	   laboratory	  assays.	  One	  hopes	  that	  this	  will	  lead	  to	  refinement	  of	  personalized	  treatment	  strategies	  in	  IBD.(54)	  	  	  Keywords:	  Inflammatory	  bowel	  disease/	  trough	  levels/	  anti-­‐TNF-­‐α/l	  adapted	  strategy	  /swiss	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